SCHEMBL8740247

SCHEMBL8740247

CC(C)(C)OC(=O)N1CCC(c2c[nH]cn2)CC1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.53
MAPT P10636 1/20 0.53
THRB P10828 1/20 0.53
HTT P42858 1/20 0.51
GPR119 Q8TDV5 7/20 0.50
HPGDS O60760 1/20 0.47
ALDH1A1 P00352 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
HPGD P15428 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
JAK2 O60674 1/20 0.46
JAK1 P23458 1/20 0.46
TYK2 P29597 1/20 0.46
JAK3 P52333 1/20 0.46
DDB1 Q16531 1/20 0.46
CRBN Q96SW2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27034439 0.92 HPGDS (0.48) KDM4EMAPTTHRBHTTGPR119
SCHEMBL23149048 0.86 KDM4E (0.44) KDM4EMAPTTHRBHTTGPR119
SCHEMBL23124118 0.86 HPGDS (0.49) KDM4EMAPTTHRBHTTGPR119
SCHEMBL16892271 0.80 KDM4E (0.45) KDM4EMAPTALDH1A1NPSR1
SCHEMBL18865593 0.79 GPR119 (0.50) KDM4EMAPTTHRBHTTGPR119
SCHEMBL25631401 0.79 FAAH (0.47) KDM4EMAPTTHRBGPR119
SCHEMBL25629733 0.78 GPR119 (0.46) KDM4EMAPTTHRBHTTGPR119
SCHEMBL8175638 0.77 MAP3K12 (0.34) KDM4EALDH1A1HPGDNPSR1
SCHEMBL3861940 0.77 HTT (0.55) KDM4EMAPTTHRBHTTGPR119
SCHEMBL15878611 0.77 KDM4E (0.54) KDM4EMAPTTHRBHTTGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114874186-B Glutamine acyl cyclase isozyme inhibitor and preparation method and application thereof 深圳大学 2023-07-11 CN disclosed
CN-114874186-A Glutaminyl cyclase isoenzyme inhibitor and preparation method and application thereof 深圳大学 2022-08-09 CN disclosed
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-11325908-B2 CaMKII inhibitors and uses thereof THE JOHNS HOPKINS UNIVERSITY (US) 2022-05-10 US disclosed
EP-3189052-B1 CAMKII INHIBITORS AND USES THEREOF UNIV JOHNS HOPKINS (US) 2021-11-03 EP disclosed
US-20200385383-A1 CaMKII INHIBITORS AND USES THEREOF ALLOSTEROS THERAPEUTICS, INC. 2020-12-10 US disclosed
US-10759792-B2 CaMKII inhibitors and uses thereof THE JOHNS HOPKINS UNIVERSITY (US) 2020-09-01 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed
US-20170247374-A1 CaMKII INHIBITORS AND USES THEREOF THE JOHNS HOPKINS UNIVERSITY 2017-08-31 US disclosed
WO-2016037106-A1 CaMKII INHIBITORS AND USES THEREOF ALLOSTEROS THERAPEUTICS, INC (US) 2016-03-10 WO disclosed
US-7247725-B2 Gamma-aminoamide modulators of chemokine receptor activity MERCK & CO., INC. (US) 2007-07-24 US disclosed
US-5663350-A CHEMICAL CONDENSATION AND CATALYTIC HYDROGENATION, CYCLIZATION THE UNIVERSITY OF TOLEDO (US) 1997-09-02 US disclosed
US-5639775-A COGNITION ACTIVATORS THE UNIVERSITY OF TOLEDO (US) 1997-06-17 US disclosed
US-5380858-A Pyridyl imidazoles from an acetylpyridine and formamide or formamidine THE UNIVERSITY OF TOLEDO (US) 1995-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11325908-B2 CaMKII inhibitors and uses thereof CAMK2G, CAMK2B, CAMK1 KDM4E 2927/4885MAPT 790/4885THRB 740/4885
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 KDM4E 725/4885MAPT 4505/4885THRB 4280/4885
US-20170247374-A1 CaMKII INHIBITORS AND USES THEREOF CAMK2G, CAMK2B, CAMK1 KDM4E 2927/4885MAPT 790/4885THRB 740/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 KDM4E 723/4885MAPT 4265/4885THRB 4174/4885
US-20200385383-A1 CaMKII INHIBITORS AND USES THEREOF CAMK2G, CAMK2B, CAMK1 KDM4E 2927/4885MAPT 790/4885THRB 740/4885
US-10759792-B2 CaMKII inhibitors and uses thereof CAMK2G, CAMK2B, CAMK1 KDM4E 2927/4885MAPT 790/4885THRB 740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.